|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.450 USD | -1.97% |
|
+8.79% | -22.03% |
| 06-17 | Ocular Therapeutix, Inc. - Analyst/Investor Day | |
| 06-17 | Ocular Therapeutix Says Axpaxli New Drug Application Submission to US FDA Planned for Q4 | MT |
| Market Cap | 2.11B 1.84B 1.7B 1.59B 2.98B 199B 3B 20.17B 7.83B 98.04B 7.92B 7.75B 340B | P/E 2026 * |
-6.03x | P/E 2027 * | -6.88x |
|---|---|---|---|---|---|
| Enterprise Value | 1.75B 1.52B 1.4B 1.32B 2.47B 165B 2.49B 16.7B 6.49B 81.18B 6.56B 6.42B 281B | EV / Sales 2026 * |
33.7x | EV / Sales 2027 * | 17.2x |
| Free-Float |
99.08% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ocular Therapeutix, Inc.
| 1 day | -1.92% | ||
| 1 week | +8.79% | ||
| Current month | +5.05% | ||
| 1 month | +12.95% | ||
| 3 months | +11.48% | ||
| 6 months | -27.08% | ||
| Current year | -22.03% |
| 1 week | 8.62 |  | 10.39 |
| 1 month | 7.86 | | 10.39 |
| Current year | 6.23 | | 13.03 |
| 1 year | 6.23 | | 16.44 |
| 3 years | 2 | | 16.44 |
| 5 years | 2 | | 16.44 |
| 10 years | 2 | | 24.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pravin Dugel
CEO | Chief Executive Officer | 62 | 2024-04-14 |
Jason Robins
DFI | Director of Finance/CFO | 50 | 2026-01-19 |
Nadia Waheed
CTO | Chief Tech/Sci/R&D Officer | 49 | 2024-05-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Charles Warden
CHM | Chairman | 57 | 2019-06-30 |
| Director/Board Member | 78 | 2012-11-04 | |
Leslie Williams
BRD | Director/Board Member | 66 | 2019-03-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-09 | Free | Executive/Senior Manager | 29,465 | 0.0139% | ||
| 06-09 | Free | Director | 58,000 | 0.0274% | ||
| 06-09 | Free | Director | 58,000 | 0.0274% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.97% | +8.79% | +13.63% | +103.11% | 2.11B | |
| -0.85% | -5.14% | +40.29% | +143.68% | 992B | |
| -1.94% | -3.89% | +51.96% | +39.56% | 564B | |
| -2.15% | -3.66% | +16.74% | +57.12% | 391B | |
| -2.90% | +0.68% | +24.66% | +16.53% | 330B | |
| -2.36% | -3.12% | +24.71% | +12.95% | 280B | |
| -2.45% | -2.88% | +24.29% | +29.93% | 279B | |
| -1.91% | -0.87% | -41.95% | -48.26% | 196B | |
| -1.78% | -5.10% | +16.01% | +46.99% | 184B | |
| -2.05% | -2.18% | +14.00% | +58.44% | 156B | |
| Average | -2.12% | +1.40% | +18.43% | +46.00% | 337.33B | |
| Weighted average by Cap. | -1.89% | -0.48% | +28.03% | +63.16% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 51.91M 45.23M 41.69M 39.22M 73.37M 4.89B 73.88M 496M 193M 2.41B 195M 191M 8.36B | 122M 106M 97.6M 91.8M 172M 11.45B 173M 1.16B 451M 5.64B 456M 446M 19.56B |
| Net income | -362M -315M -290M -273M -511M -34.07B -515M -3.45B -1.34B -16.79B -1.36B -1.33B -58.2B | -329M -287M -264M -249M -465M -31.01B -468M -3.14B -1.22B -15.28B -1.23B -1.21B -52.96B |
| Net Debt | -363M -316M -292M -274M -513M -34.21B -517M -3.47B -1.35B -16.86B -1.36B -1.33B -58.44B | -18M -15.68M -14.46M -13.6M -25.44M -1.7B -25.62M -172M -66.8M -836M -67.56M -66.12M -2.9B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-18 | 9.460 $ | -1.87% | 3,457,896 |
| 26-06-17 | 9.640 $ | +7.83% | 7,403,976 |
| 26-06-16 | 8.940 $ | -0.56% | 2,329,712 |
| 26-06-15 | 8.990 $ | +0.56% | 2,467,340 |
| 26-06-12 | 8.940 $ | +2.76% | 2,696,811 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- OCUL Stock
Select your edition
All financial news and data tailored to specific country editions
